Phayronet develops a unique valve implanted with the tiny-invasive method and meant to solve health issues caused by a poorly-functioning heart valve (MR).

LaboratoryWe at Phayronet are developing a tiny-invasive solution for a poorly functioning heart valve. A flaw in the valve mainly occurs by heart-tissue scarring triggered by a heart attack that causes a distortion or an expansion of the heart's left chamber, which prevent the valve from completely shutting down and appropriately blocking the blood flow. As a result, a leak occurs, blood pressure in the lungs increases, pulmonary edema sets in, and the patient's life is at risk. The product that Phayronet developed is fitted on the existing valve and works simultaneously with it to improve heart activity, which in turn can also be suitable for patients whose valve is not functioning properly to withstand the only currently-available procedure.

Phayronet's unique technology continues to make inroads and generates a great deal of interest in Israel and around the world.

Phayronet is developing a solution for diabetic retinopathy, which is a major cause of blindness and disability in the West. The new method, developed in collaboration with the Technion, will enable experts to quickly identify and treat microscopic aneurysm that poses a high leak risk, as the treatment should reduce the size of the edema and save the lung. Furthermore, our scientists make groundbreaking achievements in targeted therapy and clinical diagnosis by the use of vWF protein, as they can demonstrate that it is used as a marker for the hazardous areas in the reticulum. An early diagnosis of the high-risk areas will make diabetic retinopathy treatment a preventative and not a reactive treatment that should preserve eyesight and save millions of dollars in medical expenses.